Risperdal Consta and Health Care Utilization in Patients With Schizophrenia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if Risperdal Consta will affect the healthcare
utilization costs in chronically ill schizophrenic patients with multiple admissions to the
psychiatric hospital compared to the previous utilization costs under standard oral treatment
of any atypical antipsychotic. We hypothesize that higher Risperdal Consta acquisition costs
can be offset by reduction in total medical utilization costs, such as hospitalizations, ER
visits, unscheduled outpatient visits or incarcerations due to worsening of psychotic
symptoms.
Phase:
Phase 4
Details
Lead Sponsor:
Emory University
Collaborator:
Janssen, L.P. - Investigator Initiated Studies Program